1187385-87-0 Usage
Uses
Used in Pharmaceutical Industry:
1-Ethyl-6-fluorobenzoimidazole is used as a potential anti-cancer agent for its ability to inhibit the activity of enzymes and biological processes that contribute to cancer cell growth and proliferation. It is being studied for its efficacy in targeting and managing cancerous cells.
Additionally, it is used as a neurotransmitter receptor antagonist, leveraging its capacity to interact with specific receptors in the nervous system, which may have implications for the treatment of neurological disorders.
Furthermore, 1-Ethyl-6-fluorobenzoimidazole is utilized as a building block in the synthesis of other bioactive compounds, indicating its versatility in drug development and the creation of novel therapeutic agents.
As research progresses, the full spectrum of potential applications and biological activities of 1-Ethyl-6-fluorobenzoimidazole is expected to be explored, potentially expanding its use across various medical and pharmaceutical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1187385-87-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,7,3,8 and 5 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1187385-87:
(9*1)+(8*1)+(7*8)+(6*7)+(5*3)+(4*8)+(3*5)+(2*8)+(1*7)=200
200 % 10 = 0
So 1187385-87-0 is a valid CAS Registry Number.
1187385-87-0Relevant academic research and scientific papers
METALLOENZYME INHIBITOR COMPOUNDS
-
, (2018/07/29)
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
BENZIMIDAZOLE DERIVATIVES AND USES THEREOF
-
Paragraph 0300, (2015/12/31)
Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.
